Morgan Stanley began coverage on shares of Ascendis Pharma A/S (NASDAQ:ASND) in a research report sent to investors on Friday morning, BenzingaRatingsTable reports. The firm issued an overweight rating and a $128.00 price objective on the biotechnology company’s stock.
Several other equities research analysts also recently commented on ASND. ValuEngine downgraded Ascendis Pharma A/S from a buy rating to a hold rating in a report on Wednesday, October 2nd. Zacks Investment Research upgraded Ascendis Pharma A/S from a sell rating to a hold rating in a report on Tuesday, August 27th. Wedbush set a $191.00 price objective on Ascendis Pharma A/S and gave the stock a buy rating in a report on Tuesday, September 24th. JPMorgan Chase & Co. lifted their price objective on Ascendis Pharma A/S from $143.00 to $152.00 and gave the stock an overweight rating in a report on Thursday, August 29th. Finally, BidaskClub downgraded Ascendis Pharma A/S from a sell rating to a strong sell rating in a report on Thursday, September 12th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and eight have assigned a buy rating to the stock. The company currently has a consensus rating of Buy and a consensus price target of $146.13.
Shares of NASDAQ:ASND opened at $94.61 on Friday. The company has a market cap of $4.01 billion, a P/E ratio of -25.30 and a beta of 0.62. The company has a debt-to-equity ratio of 0.05, a quick ratio of 11.59 and a current ratio of 11.59. Ascendis Pharma A/S has a one year low of $53.21 and a one year high of $133.96. The business’s 50-day simple moving average is $103.19 and its 200 day simple moving average is $114.02.
Ascendis Pharma A/S (NASDAQ:ASND) last announced its earnings results on Wednesday, August 28th. The biotechnology company reported ($1.40) EPS for the quarter, missing the consensus estimate of ($1.32) by ($0.08). The company had revenue of $3.61 million for the quarter, compared to analysts’ expectations of $0.68 million. Ascendis Pharma A/S had a negative net margin of 932.52% and a negative return on equity of 35.99%. Analysts predict that Ascendis Pharma A/S will post -5.36 earnings per share for the current year.
A number of hedge funds have recently bought and sold shares of ASND. NumerixS Investment Technologies Inc purchased a new stake in Ascendis Pharma A/S during the 1st quarter worth approximately $94,000. Marshall Wace LLP increased its holdings in Ascendis Pharma A/S by 60.6% during the 1st quarter. Marshall Wace LLP now owns 28,948 shares of the biotechnology company’s stock worth $3,407,000 after purchasing an additional 10,921 shares during the last quarter. Marshall Wace North America L.P. increased its holdings in Ascendis Pharma A/S by 56.4% during the 1st quarter. Marshall Wace North America L.P. now owns 1,161,476 shares of the biotechnology company’s stock worth $136,706,000 after purchasing an additional 418,717 shares during the last quarter. FMR LLC increased its holdings in Ascendis Pharma A/S by 11.6% during the 1st quarter. FMR LLC now owns 4,692,707 shares of the biotechnology company’s stock worth $552,332,000 after purchasing an additional 489,461 shares during the last quarter. Finally, Sphera Funds Management LTD. increased its holdings in Ascendis Pharma A/S by 17.2% during the 1st quarter. Sphera Funds Management LTD. now owns 68,273 shares of the biotechnology company’s stock worth $8,036,000 after purchasing an additional 10,000 shares during the last quarter.
Ascendis Pharma A/S Company Profile
Ascendis Pharma A/S, a clinical stage biopharmaceutical company, develops various prodrug therapies for unmet medical needs. The company develops TransCon human growth hormone, which is in Phase III clinical study in children to treat growth hormone deficiency; TransCon parathyroid hormone that is in Phase I clinical study for treating hypoparathyroidism; and TransCon C-type natriuretic peptide for the treatment of achondroplasia.
Featured Story: How is a buy-side analyst different from a sell-side analyst?
Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.